Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06370013 | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | available | — | — | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2026source: clinicaltrials